Oligonucleotide therapeutics are an emerging drug modality, which consists of modified or unmodified short nucleic acid molecules, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), aptamers, and DNAzymes. Oligonucleotide therapeutics can bind to an RNA target by Watson-Crick base pairing. This binding recruits RNAseH, which induces cleavage and degradation of the target RNA. The mechanism can be used to specifically change the expression of disease-relevant proteins. Thus, oligonucleotides are an attractive drug modality that has gained increasing interest in the past years.
Oligonucleotide therapeutics are made from nucleotides containing genetic code, so these therapeutics are very specific and targeted. In some cases, oligonucleotide therapeutics may be customized at an individual level.
Creative Bioarray has been working in this area for many years and has been involved in several oligo projects. We have a certain understanding of the chemistry involved in the synthesis of oligonucleotide drug substances and can communicate with our customers about their processes. In addition, owing to our experience with numerous oligo manufacturing projects, Creative Bioarray has developed internal templates, allowing us to reach a fundamental level of design very quickly. Our template documents facilitate the efficient implementation of the oligo projects, which also helps our customers reduce the time to the clinic and the market. As a result, Creative Bioarray is a partner who can hear and understand the needs of our customers and rapidly provide tailor-made solutions.
Creative Bioarray provides synthesis services for a wide range of oligonucleotides (DNA, RNA) and derivatives, including natural DNA, siRNA, mRNA, and DNA/RNA oligos, or non-natural and more stable oligonucleotides. As an open and integrated platform with technology and talent advantage, Creative Bioarray's oligonucleotide synthesis platform is committed to providing high-quality services to different customers, facilitating the development of nucleic acid drugs.
The unique charge and polymeric structure of oligonucleotides make the analytical characterization particularly challenging. Selection of appropriate analytical techniques depends on the molecule size, higher order structure and chemical composition/modifications. We use a set of analytical methods to evaluate the physicochemical and biophysical properties of oligonucleotides, including mass spectrometry-based technology, chromatographic technology, electrophoresis, particulates analysis and hybrid technology.
|Identity||HRMS, IP-RP-LC, cSDS, IEX cIEF|
|Purity||IP-RP-LC, LC-MS, cSDS, IEX|
|pI/Charge Variants||cIEF, IEX|
|Size/Aggregation||DLS, MALS, SEC|
|Sequence Confirmation||LC-MSMS fragmentation|
Creative Bioarray can help you advance your project, contact us now to discuss further with our accessible and specialized team.